At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 9 target
Drug / intervention
HBV mRNA vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of mRNA Vaccine for Patients With HBV-positive Advanced Hepatocellular Carcinoma
In Brief
A Phase 1 clinical trial evaluating HBV mRNA vaccine for Liver Cancer and Hepatocellular Carcinoma. Targeting 9 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of mRNA vaccine for HBV-positive Advanced Hepatocellular Carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer, Hepatocellular Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
202420252026
Enrollment StartFeb 2023
First PostedFeb 2023
Primary CompletionJan 2024
Study CompletionJan 2025
TodayJul 2026
First PostedFeb 22, 2023
Enrollment StartFeb 15, 2023
Primary CompletionJan 1, 2024
Study CompletionJan 1, 2025
TodayJul 1, 2026
Enrollment to primary: 11 monthsPosted 3.4 years ago
Interventions
HBV mRNA vaccinebiological
With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.